Novavax and Takeda previously announced a licensing agreement and are collaborating on manufacturing, clinical development and regulatory activities in Japan. Takeda anticipates the capacity to manufacture more than 250 million doses of Novavax’ COVID-19 vaccine per year.

https://ir.novavax.com/Novavax-Statement-on-Takeda-Agreement-to-Provide-150-Million-Doses-of-NVX-CoV2373-to-the-Government-of-Japan